In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo
| EPIC: | GWP |
| Market: | AIM |
| Sector: | Pharma & Biotech |
| Website: | www.gwpharm.com |
GW Pharmaceuticals
GW Pharmaceuticals was founded in 1998 and listed on AIM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex® Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications...
GW Pharmaceuticals is traded in the ISDX Exchange HERE
col 5
col 6
GW Pharmaceuticals Timeline
Ideally you are looking at dips to the 50-day line at £6.29 - Zak Mir.
Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.
GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.
Analysts say the drug has the potential to deliver annual sales of around US$800mln.
Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.
GW Pharmaceuticals says it is on track to file a New Drug Application for its cannabis-based epilepsy treatments following positive Phase III trials.
It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.
The trial results were described as “very exciting” by medical expert Linda Laux.
GW Pharmaceuticals advances its cannabis-based drug repertoire with FDA approval.
Shares rocketed 120% on the back of promising phase three trial results for its cannabis-based epilepsy drugs.
